OBJECTIVE To describe updated national estimates and characteristics of health care-and community-associated invasive methicillin-resistant Staphylococcus aureus (MRSA) infections in 2011.
istrative data documented increases in the number of estimated hospitalizations in which International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes indicating MRSA infection were present. 6, 7 However, recent reports of surveillance programs in geographically distinct areas suggest there have been recent declines in the incidence of the most serious types of MRSA infections (ie, bloodstream infections), including those among critical care patients in US hospital settings 2, 8 and both community-and hospital-onset MRSA bacteremia among military families, active duty personnel, and military retirees starting in 2005. 9 The Emerging Infections Program-Active Bacterial
Core surveillance system (EIP-ABCs) at the Centers for Disease Control and Prevention (CDC) has been tracking invasive MRSA infections in 9 diverse US metropolitan areas since 2005. Reports using this system documented an 11% annual decline in the incidence of hospital-onset MRSA bloodstream infections between 2005 and 2008 in these metropolitan areas. 2 The cause of these declines is uncertain but may be due to improvements in hospital-based infection prevention practices, improved early management of noninvasive infections, or changes in the virulence of the circulating strains. A prior CDC study estimated the national burden of invasive MRSA in 2005 3 ; however, this report did not adjust for dialysis or include patients with recurrent infections. 10 Therefore, to better understand the current national burden of these most serious MRSA infections, spanning both community and health care settings, we used EIP-ABCs' data and updated methodology to describe the types and outcomes of invasive MRSA infections in 2011 and to estimate the infection burden in the United States in 2011 and 2005. These estimates are necessary to improve the assessment of invasive MRSA infection nationally, to inform prevention policies in health care settings, and to measure progress toward public health goals.
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Methods
Human Subjects Considerations
This surveillance activity was reviewed by human subject personnel at the CDC and was determined to be nonresearch. Local institutional review boards also reviewed when indicated and approved this activity.
Invasive MRSA Surveillance
The EIP-ABCs is a population-based surveillance system used by the CDC and collaborating agencies and organizations to estimate the incidence of invasive MRSA infections in selected counties in 9 US states (California, Colorado, Connecticut, Georgia, Maryland, Minnesota, New York, Oregon, and Tennessee). The methods of surveillance have been described previously, 3 with modifications to include recurrent infections (ie, multiple infections in a single patient during the calendar year) in incidence calculations. 
Definitions
Cases were classified as (1) "hospital onset," if culture was obtained after hospital day 3 (with admission being day 1), (2) "health care-associated community onset" (HACO) if culture was obtained as an outpatient on or before hospital day 3 in a patient with a documented health care risk factor, or (3) "community associated" if culture was obtained as an outpatient or before hospital day 3 in a patient without documentation of a health care risk factor. Of note, the definition of hospitalonset infections differ from previous reports where MRSA culture was obtained after hospital day 2 in prior methods; this refinement is consistent with classifying MRSA bloodstream infections as hospital-onset in the National Healthcare Safety Network's (NHSN) Laboratory Identified Event Reporting and is applied to all analysis in this article. Cases were classified as a bloodstream infection if they had a positive blood culture for MRSA. Bloodstream infection cases were further classified as either (1) an access infection (physician-documented arteriovenous fistula, dialysis access site, or CVC exit site infection), an infection of uncertain focus either (2) with a CVC present or (3) without a CVC present, or (4) as having other infection foci if there were either positive MRSA cultures from sterile sites other than blood or additional infectious clinical diagnosis in the admission or discharge summary. An MRSA clinical diagnosis of bacteremia, pneumonia, osteomyelitis, or other infection was assigned to each case based on documentation of such diagnosis in the admission or discharge summary or by the sterile site from which MRSA was isolated. Each case was assigned additional MRSA clinical diagnosis if multiple diagnoses (eg, bacteremia and osteomyelitis) were documented within 30 days of the initial MRSA culture. Health care-associated infection criteria defined by the NHSN were not applied to cases because NHSN definitions only apply to infections not present on admission.
Cases with a clinical diagnosis of pneumonia were further classified as having confirmed lower respiratory tract infections if radiographic evidence was present (ie, broncho-
Statistical Analysis
Differences in baseline characteristics among cases in each epidemiologic category (hospital onset, HACO, and community associated) were analyzed using the χ 2 test or Fisher exact test (where appropriate) for categorical variables and the Wilcoxon rank sum test for continuous variables. Overall, 9% of cases were reported with unknown race in medical charts. To facilitate extrapolation to national estimates, cases for which the race was unknown were assigned a race based on the known population distributions of race by sex, age, and receipt of chronic dialysis in each surveillance site. National estimates were determined by calculating EIP-ABC-specific incidence rates stratified by age group, race, sex, and receipt of dialysis, and extrapolated nationally by multiplying each stratum-specific incidence rate by the national population estimate for each stratum based on US census and US Renal Data System data. [15] [16] [17] [18] In previous reports and publications, national estimates were adjusted for only age, race, and sex. 3 Confidence intervals for nationally estimated incidence rates of disease and mortality were calculated based on the gamma distribution. 19 Analyses were performed using SAS statistical software, version 9.3 (SAS Institute Inc), and Stata version 11.1 (StataCorp). We defined statistical significance as P ≤ .05 for a 2-tailed test.
Results
Case Characteristics
The EIP-ABCs sites reported 4872 cases of invasive MRSA infections among 4445 persons (8% had >1 infection) in 2011. Among these cases, 4746 cases (97%) were classified into epidemiological classes: 2912 (60%) were HACO, 868 (18%) were hospital onset, and 966 (20%) were community associated ( Table 1) . The median age of cases was 61 years (range, 0-103 years) ( Table 1 ). The majority of cases were male (60%) and of either white (56%) or black (32%) race. Diabetes was a diagnosis in 41% of cases. There was receipt of hemodialysis or peritoneal dialysis within the year before invasive MRSA infection in 21% of cases (61% of cases receiving dialysis also had diabetes).
Most invasive MRSA infections had a positive blood culture (3907 [80%]) and were classified as a bloodstream infection ( Table 2) . Overall, 55% of infections had a nonvascular focus, and 45% had a vascular or nonspecific focus (Table 2) . Among the 760 invasive MRSA infections with cliniciandefined pneumonia, based on radiographic and respiratory specimen findings, 293 (31%) had confirmed MRSA lower respiratory tract infections (eTable in the Supplement). Other common MRSA syndromes included skin infections (1081 [22%]) and osteomyelitis (629 [13%]) ( Table 2 ). There were 650 in-hospital deaths (13%), and the majority of these were within 7 days of initial MRSA culture (393 [60%]).
Health Care-Associated Infections
Health Care-Associated Community-Onset Infections Of the 3780 health care-associated cases, 2912 (77%) had onset in the community and were classified as HACO; median age was 64 years, 59% were male, and 34% were black ( Table 1 
Hospital-Onset Infections
Underlying conditions among hospital-onset cases were similar to health care-associated community-onset cases except as previously noted. Among hospital-onset cases, 26% were in the intensive care unit, whereas 49% were in other inpatient wards ( e HO significantly different from non-HO (P < .01).
f CA significantly different from non-CA (P < .001). g HACO and HO significantly different (P < .001).
h For infants younger than 12 months, hospitalization for a normal delivery was not counted as a hospitalization. i HACO and HO not significantly different (P = .40). (5) 48 (6) 73 (8) 277 (6) .02
Urinary tract infection 191 (7) 33 (4) 56 (6) 285 (6) .009
Surgical site infection 119 (4) 15 (2) 11 (1) the estimated national rate of invasive MRSA has decreased by 31.2%. Although this rate decrease was most precipitous among hospital-onset infections, at 54.2%, rate decreases were evident among other categories as well: health careassociated community-onset by 27.7% and communityassociated infections by 5.0%. An estimated 11 285 (95% CI, 8039-16 545) persons with invasive MRSA infections died of all causes during their hospitalizations in 2011 (Table 3) ; of these estimated deaths, 6071 (95% CI, 3926-9722) had health care-associated communityonset, 3126 (95% CI, 1589-6419) had hospital-onset, and 1764 (95% CI, 935-3241) had community-associated infections.
Discussion
In 2011, we estimated the overall number of invasive MRSA infections was 80 461; 31% lower than when estimates were first available in 2005. Also, for the first time since the CDC began tracking invasive MRSA infections nationally, the estimated incidence of invasive hospital-onset infections is lower than that among persons residing in the community without significant health care contact. However, the largest burden of disease remains among patients with infection onset outside of acute care hospitals but with recent or ongoing exposure to While prior studies focused on invasive MRSA incidence for a specific population or region, 9,20 our study used data from the largest US population surveillance system for invasive MRSA to provide robust national burden estimates of this disease. The methodology in this study was improved from our prior methods 3 (and applied to historical 2005 data) by (1) 24 ,25 making it unlikely that the reductions in hospital-onset MRSA we observed could be attributable to reductions in length of hospital stays. It is notable that the incidence of community-associated invasive MRSA infections, although relatively stable, has not increased over this time, despite increases in hospitalizations related to MRSA skin and soft-tissue infections (ie, mostly noninvasive infections) documented in discharge data. 7 Progress in reducing infections among this population is likely to be most challenging due to a lack of clearly effective strategies to control endemic MRSA transmission in the community setting. While guidance exists for the prevention of transmission in some institutions such as schools, athletic facilities, and correctional facilities, 26 prevention of communityassociated MRSA transmission outside of these settings is not well described. Changes in this setting may related to transmission in households, prevention of invasive disease from improved early treatment of noninvasive infections, 27 or the natural evolution of this pathogen. Approximately 78% of all invasive MRSA infections in 2011 had onset in the outpatient or community setting (health careassociated community-onset and community-associated infections), an increase from 72% in 2005. Of these infections, 77% were classified as HACO, which comprised mostly recently discharged patients, long-term care residents, and dialysis patients. The moderate decrease of these infections could be attributable to decreased transmission in hospital settings or prevention efforts outside of the acute care hospital. Among nondialysis cases with prior hospitalization, nearly twothirds developed their infections within 3 months of hospital discharge. This suggests a higher risk of invasive MRSA in the weeks following hospitalization. Invasive devices that remain placed during the postdischarge period, progression from colonization to clinical infection, and breakdowns in host defense and skin integrity during hospitalization may account for this increased risk. Further research is needed to understand (1) risk factors for progression of colonization and noninvasive infection to invasive infections and (2) transmission dynamics within health care settings after discharge from acute care hospitals. Significant progress in preventing invasive MRSA infections in the dialysis and postdischarge settings is needed to substantially reduce the overall burden of invasive MRSA infections.
There are several limitations to this study. First, although this program operates in several metropolitan areas with diverse populations, these specific areas were not randomly selected to be representative; however, when calculating national estimates, we adjusted for regional differences in sex, age, race, and use of dialysis to produce estimates that more accurately represent the entire US population. In addition, this surveillance system does not track MRSA colonization or noninvasive MRSA infections, such as skin and soft-tissue infections. Therefore, we cannot draw any conclusions about the relatedness between MRSA colonization or prior noninvasive infection and invasive infection. However, this system was designed to create national estimates capturing infections in both inpatient and outpatient settings and therefore delivers a more comprehensive assessment of invasive MRSA than systems focused predominantly on acute care facility-specific performance measures, including NHSN.
In conclusion, a substantial decrease in the national burden of invasive MRSA infections has been observed in the United States between 2005 and 2011, with the largest de- Research Original Investigation National Burden of Invasive MRSA Infections
